The FDA approved a treatment for a genetic disease called spinal muscular atrophy that causes infants' muscles to waste away, potentially killing them before age 2. The price tag? $2.125 million for a one-time treatment.
And then came the price tag: $2.125 million for a one-time treatment.The gene therapy, called Zolgensma, will be marketed by AveXis, whose parent company is Novartis. Eli Lilly's lower-priced insulin goes on sale amid drug price debate"Today's approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases," Dr. Ned Sharpless, the FDA's acting commissioner, said in a statement Friday.
In a CNBC op-ed last week, Novartis CEO Dr. Vas Narasimhan called for a new pricing and payment model for one-time treatments like Zolgensma, versus other treatments with costs that accumulate over time."Health-care systems, however, are accustomed to treating chronic diseases with a pay-as-you-go model, spreading costs over months and years," Narasimhan said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA approves Novartis' $2.1 million gene therapy — making it the world's most expensive drugThe therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every 11,000 live births.
Lire la suite »
The FDA just approved a new treatment for a devastating disease. The price tag is more than $2 million.The treatment, called Zolgensma, should work longer than the typical drug, but also has a much higher price tag.
Lire la suite »
“Best if used by.FDA supports manufacturers’ use of the phrase “Best If Used By” to cut down on date confusion
Lire la suite »
Is Tahini safe? More brands recalled over Salmonella outbreak linkThe FDA are advising people not to eat Karawan, El-Karawan, or SoCo labeled tahini products.
Lire la suite »
U.S. FDA labels J&J surgical staplers' recall as severestThe U.S. Food and Drug Administration warned of risks of serious injury or death...
Lire la suite »
FDA proposes changing name of a healthier alternative to sodiumWhat's in a name? The FDA hopes changing how a salt alternative is listed on ingredient labels will reduce Americans' sodium intake.
Lire la suite »
Commentary: We need to make sure new drug cures don't widen income gap for the poorCommentary: We need to make sure new drug cures don’t widen the income gap for the poor, former FDA Commissioner ScottGottliebMD says. The HealthyReturns conference in NYC kicks off tomorrow! Follow cnbcevents for the latest.
Lire la suite »